Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.41% | -53.08% | -99.87% | -99.89% | -99.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.41% | -53.08% | -99.87% | -99.89% | -99.92% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -4.41% | -53.08% | -99.87% | -99.89% | -99.92% |
| SG&A Expenses | -14.06% | -22.31% | -36.77% | -40.02% | -40.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -49.57% | -31.64% | -15.57% | 20.19% | 38.21% |
| Total Operating Expenses | -8.23% | -11.07% | -13.58% | -12.75% | -9.65% |
| Operating Income | 8.23% | 11.05% | -7.11% | -7.40% | -32.34% |
| Income Before Tax | -46.50% | -46.18% | -7.31% | -0.36% | -25.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.50% | -46.18% | -7.31% | -0.36% | -25.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.50% | -46.18% | -7.31% | -0.36% | -25.51% |
| EBIT | 8.23% | 11.05% | -7.11% | -7.40% | -32.34% |
| EBITDA | 7.99% | 11.76% | -8.22% | -8.00% | -35.24% |
| EPS Basic | -34.24% | -36.58% | -5.48% | 1.25% | -23.67% |
| Normalized Basic EPS | 14.88% | 15.87% | -5.76% | -1.76% | -26.88% |
| EPS Diluted | -34.24% | -36.58% | -5.48% | 1.25% | -23.67% |
| Normalized Diluted EPS | 14.88% | 15.87% | -5.76% | -1.76% | -26.88% |
| Average Basic Shares Outstanding | 7.75% | 4.18% | 1.82% | 1.62% | 1.50% |
| Average Diluted Shares Outstanding | 7.75% | 4.18% | 1.82% | 1.62% | 1.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |